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Introduction
Marshall Syndrome or PFAPA is an inflammatory periodic
disease characterized by periodic fever, aphthous stomati-
tis, pharyngitis and cervical adenitis. Restless, headache,
abdominal pain, vomiting, hepatosplenomegaly and
arthralgia are less common symptoms seeing in this
disease. The diagnosis is established on the basis of clinical
criteria that require the presence of a recurrent fever of
early onset (<5 years) and ≥1 of the 3 associated symptoms
(aphthosis, cervical adenitis, and pharyngitis), in the
absence of upper respiratory tract infections and cyclic
neutropenia.
Objectives
Although PFAPA is an auto inflammatory disease, it
doesn’t have genetic basis such as other periodic fevers.
This study evaluates the 12 common MEFV gene muta-
tions in patients with PFAPA syndrome.This study evalu-
ates the 12 common MEFV gene mutations in patients
with PFAPA syndrome.
Methods
21 patients with PFAPA syndrome who had diagnostic
criteria were enrolled in this study and 12 common MEFV
gene mutations were evaluated in them. The 12 most
common MEFV gene mutations (P369S, F479L, M680I
(G / C), M680I (G / A), I692del, M694V, M680I, K695R,
V726A, A744S, R761H, E148Q) were analyzed by using
amplification refractory mutation system for 11 of the first
and the PCR was performed for E148Q.
Results
The age of patients was between 6 months to 14 years old,
and 15 were male. Seven patients had heterozygote and
one had compound heterozygote (K695R, V725A) muta-
tion. There were 4 alleles M694V, 3 alleles V726A, 1 allele
E148Q and 1 allele K694R. No significant difference
between mutated patients with non-mutated in symptoms
like aphthous and stomatitis, duration of attacks, episodes
of fever and response to treatment. Gaslini score test was
not helpful to predict the probability of gene mutations.
Conclusion
About 30 percent of patients had MEFV gene mutations
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